Athar Shamim

Athar Shamim

Auto-generated profile, based on publicly available information

Athar Shamim

Nanotechnology Lab, Dept of Pharmaceutics, School of Pharmaceutics Education and Research (SPER), Jamia Hamdard, New Delhi, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in ACS Omega
Verified
Journal Article
Open access
ASAthar Shamim
Athar Shamim
Mohammad Javed AnsariMohammad Javed Ansari
Mohammad Javed Ansari
Alhussain H. AodahAlhussain H. Aodah
Alhussain H. Aodah
Muzaffar IqbalMuzaffar Iqbal
Muzaffar Iqbal
MAMohd. Aqil
Mohd. Aqil
AAAsgar Ali
Asgar Ali
In the given study, a new reverse-phase high-performance liquid chromatography (RP-HPLC) method has been reported for the simultaneous estimation of ciprofloxacin hydrochloride (CPX) and rutin (RUT) using quality by design (QbD) approach. The analysis was carried out by applying the Box-Behnken design having fewer design points and less experimental runs. It relates between factors and responses and gives statistically significant values, along with enhancing the quality of the analysis. CPX and RUT were separated on the Kromasil C18 column (4.6 × 150 mm, 5 μm) using an isocratic mobile phase combination of phosphoric acid buffer (pH 3.0) and acetonitrile with the ratio of 87:13% v/v at a flow rate of 1.0 mL/min. CPX and RUT were detected at their respective wavelengths of 278 and 368 nm using a photodiode array detector. The developed method was validated according to guideline ICH Q2 R (1). The validation parameters taken were linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability which were in the acceptable range. The findings suggest that the developed RP-HPLC method can be successfully applied to analyze novel CPX-RUT-loaded bilosomal nanoformulation prepared by thin-film hydration technique.

27 April 2024 in RSC Pharmaceutics
Verified
Journal Article
Open access
PDF file
AFAbdul Nafey Faheem
Abdul Nafey Faheem
AAAhsan Ali
Ahsan Ali
ASAthar Shamim
Athar Shamim
SMSradhanjali Mohapatra
Sradhanjali Mohapatra
ASAyesha Siddiqui
Ayesha Siddiqui
MMMohd Aamir Mirza
Mohd Aamir Mirza
Osteoarthritis (OA) is a chronic degenerative condition characterized by the wearing down of the articulating surfaces of the tibia–femoral joint.

11 June 2024 in RSC Pharmaceutics
Verified
Journal Article
Open access
PDF file
TATalha
Talha
AAAhsan Ali
Ahsan Ali
SMSradhanjali Mohapatra
Sradhanjali Mohapatra
ASAyesha Siddiqui
Ayesha Siddiqui
UFUzma Farooq
Uzma Farooq
ZIZeenat Iqbal
Zeenat Iqbal
Worldwide, osteoarthritis is a significant cause of pain, disability, and socioeconomic losses. The disorder's epidemiology is diverse and complicated. Chondrocyte viability and function are compromised by oxidative stress, mechanical stress, and inflammatory mediators. This reprogrammes the cells to undergo hypertrophic differentiation and early “senescence” and increases their susceptibility to pro-catabolic and pro-inflammatory mediators. Given the above discussed pathophysiology of osteoarthritis, it is anticipated that the combination of oxaprozin and gaultheria oil (utilized in traditional medicine for rheumatoid arthritis) will definitely help alleviate the multifactorial disease. The objective of the research was to develop and assess a nanoemulsion gel/nanoemulgel (NEG) by combining oxaprozin, a non-steroidal anti-inflammatory drug (NSAID), and gaultheria oil using Carbopol 974 as a gelling agent. The aqueous titration method was used to create the nanoemulsion by plotting a pseudo-ternary phase diagram, and Smix was used to draw the phase diagram. The formulation was optimized by employing the design of the experiment and incorporated into Carbopol 974 to formulate the NEG. Various properties of the developed formulation, such as the vesicular size, polydispersity index (PDI), zeta potential, morphology and thermodynamic stability, were tested. Furthermore, pH, homogeneity, spreadability, extrudability, texture, bioadhesion, stability, and skin irritation were assessed for the NEG. Additionally, in vitro and ex vivo tests were conducted for the assessment of the improved formulation. The result shows that the nanoemulsion has a vesicular size of 196.2 nm with good PDI and a zeta potential of −12.33 mV. Furthermore, the results show that the NEG had a biphasic release pattern with a percent cumulative drug release (%CDR) of 78.123 after 25 h. The optimized formulation was also found to be stable at 4 °C for up to 4 weeks. Furthermore, the NEG shows good drug penetration and sustained drug release pattern, which may facilitate the transport of oxaprozin and gaultheria oil through joint tissues, resulting in longer pain alleviation and decreased inflammation. In conclusion, the new formulation would be a good choice for topical medication delivery to improve the oil and oxaprozin combined therapeutic efficacy in the management of osteoarthritis.